Rising Sexually Transmitted Infection (STI) Rates Propel Growth In Genital Warts Market: A Significant Driver Propelling The Genital Warts Market In 2025

The Genital Warts Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].

What Is the Genital Warts Market Size and Projected Growth Rate?
The genital warts market has grown strongly in recent years. It is set to increase from $1.97 billion in 2024 to $2.08 billion in 2025, with a compound annual growth rate (CAGR) of 5.7%. Factors contributing to this growth include the focus on patient-centered care, the increasing emphasis on early detection and treatment, the availability of therapies for self-target applications, and the rise in clinical trials and recurrence of genital warts.

The genital warts market is anticipated to witness substantial growth in the coming years, reaching $2.57 billion by 2029, at a compound annual growth rate (CAGR) of 5.4%. This growth is primarily driven by the increased use of telemedicine and digital health platforms for remote consultations and treatment monitoring, rising demand for effective and affordable treatments for STIs, the growing popularity of loop electrosurgical excision procedures, an increase in demand for interferon alfa-n3 injections, and better availability of therapies. Key trends include advancements in diagnostic technologies, a shift toward combination therapies, the growth of telehealth and online consultations, the emergence of novel therapeutic targets, and expansion into emerging markets.

Purchase the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=18374

What Are the Major Segments in the Genital Warts Market?
The genital warts market covered in this report is segmented -

1) By Drug Type: Imiquimod, Podophyllin, Podofilox, Trichloroacetic Acid
2) By Treatment: Chemical Treatment, Ablative Treatment, Preventive Treatment, Other Treatments
3) By Gender: Female, Male
4) By End Users: Hospitals, Clinics, Home Care Settings

Subsegmments

1) By Imiquimod: Imiquimod Cream 5%, Imiquimod Cream 3.75%
2) By Podophyllin: Podophyllin Resin 10%, Podophyllin Resin 25%
3) By Podofilox: Podofilox Gel 0.5%, Podofilox Solution 0.5%
4) By Trichloroacetic Acid: Trichloroacetic Acid 80-90%, Trichloroacetic Acid 50-70%

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=18374&type=smp

What Are The Driving Genital Warts Market Evolution?
The rising incidence of sexually transmitted infections (STIs) is expected to fuel the genital warts market. STIs, including genital warts caused by HPV, are spreading more widely due to higher sexual activity, inadequate protection, and limited access to preventive care. For example, the Joint United Nations Programme on HIV/AIDS reported that HIV cases grew from 38.7 million in 2021 to 39.0 million in 2022, with 1.3 million new infections that year. Thus, increasing STI prevalence is boosting the genital warts market.

Which Firms Dominate The Genital Warts Market Segments?
Major companies operating in the genital warts market are Merck & Co.Inc., AbbVie Inc, Sanofi S.A, Novartis AG, 3M Company, Teva Pharmaceutical Industries Ltd, Bausch Health Companies Inc, Sun Pharmaceuticals, Perrigo Company plc, Glenmark Pharmaceutical Inc, Taro Pharmaceutical Industries Ltd, Serum Institute of India Pvt. Ltd., ANI Pharmaceuticals Inc, Ligand Pharmaceuticals Incorporated, Orgenesis Inc, Verrica Pharmaceuticals Inc, CryoConcepts LP, CryoIQ global AB, Cassiopea Inc, Aresus Pharma Inc.

What Are the Latest Developing Trends in the Genital Warts Market?
Major corporations in the genital warts market are pioneering innovative treatment methods, such as newly conceived dermatology drugs, to tackle the difficulties experienced by those suffering from genital warts. Dermatology drugs denote recently constructed pharmaceuticals or therapeutic substances particularly tailored to treat various skin conditions including genital warts. For instance, Verrica Pharmaceuticals Inc., a dermatology pharmaceutical corporation based in the US, obtained New Chemical Entity (NCE) status for YCANTH, its prospective medication, in March 2023. YCANTH, which has finished phase 2 trials, is under development for the treatment of genital warts. Following FDA NCE status, the company enjoys minimally a five-year period of safeguard against generic competition.

Get the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/report/genital-warts-global-market-report

Which Is The Largest Region In The Genital Warts Market?
North America was the largest region in the genital warts market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the genital warts market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Frequently Asked Questions:
1. What Is the Market Size and Growth Rate of the Genital Warts Market?
2. What is the CAGR expected in the Genital Warts Market?
3. What Are the Key Innovations Transforming the Genital Warts Industry?
4. Which Region Is Leading the Genital Warts Market?

Why This Report Matters:

Competitive overview: This report analyzes the competitive landscape of the 3D imaging software market, evaluating key players on market share, revenue, and growth factors.

Informed Decisions: Understand key strategies related to products, segmentation, and industry trends.

Efficient Research: Quickly identify market growth, leading players, and major segments.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.